| 1.19 -0.05 (-4.03%) | 01-30 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 1.63 | 1-year : | 1.86 |
| Resists | First : | 1.4 | Second : | 1.6 |
| Pivot price | 1.18 |
|||
| Supports | First : | 1.08 | Second : | 0.89 |
| MAs | MA(5) : | 1.22 |
MA(20) : | 1.19 |
| MA(100) : | 1.33  |
MA(250) : | 2.34 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 24.3 |
D(3) : | 26.9 |
| RSI | RSI(14): 50 |
|||
| 52-week | High : | 8.19 | Low : | 0.92 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ MYNZ ] has closed below upper band by 45.4%. Bollinger Bands are 35.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.22 - 1.23 | 1.23 - 1.23 |
| Low: | 1.15 - 1.15 | 1.15 - 1.16 |
| Close: | 1.18 - 1.19 | 1.19 - 1.2 |
Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments on a molecular genetic basis; and research-use-only and IVD tests. The company was founded in 2008 and is based in Mainz, Germany.
Fri, 16 Jan 2026
Massive Insider Move: Major Investor Makes Colossal Bet on Mainz Biomed - TipRanks
Mon, 12 Jan 2026
Mainz Biomed expects to complete eAArly DETECT 2 study in 2026 - MSN
Mon, 19 May 2025
Mainz Biomed stock plunges to 52-week low of $2.18 amid market challenges - Investing.com
Mon, 21 Oct 2024
Mainz Biomed Highlights Growth and Innovations for 2025 - TipRanks
Wed, 26 Jan 2022
Why Mainz Biomed Stock Is Crashing Today - Nasdaq
Sat, 06 Nov 2021
Mainz Biomed (MYNZ) Stock Price, News & Analysis - MarketBeat
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 0 (M) |
| Shares Float | 9 (M) |
| Held by Insiders | 4.07e+006 (%) |
| Held by Institutions | 0.8 (%) |
| Shares Short | 310 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.615e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -2 % |
| Return on Assets (ttm) | 822 % |
| Return on Equity (ttm) | -114.4 % |
| Qtrly Rev. Growth | 659930 % |
| Gross Profit (p.s.) | -172.7 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 1.71319e+006 |
| Qtrly Earnings Growth | -5.3 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -15 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0.49 |
| Dividend | 0 |
| Forward Dividend | 173180 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|